TY - JOUR T1 - Comparative analysis of pneumonia in patients with drug dependence with HIV infection and without HIV JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2030 VL - 56 IS - suppl 64 SP - 2030 AU - Elena Klester AU - Karolina Klester AU - Alexandra Balitskaya AU - Alexander Zharikov Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2030.abstract N2 - Objective: to study the features of the clinical course of septic pneumonia in injecting drug users with and without HIV.Materials and Methods: 167 patients (124 were males, mean age - 32,8 ±6,7 years)- parenteral drug addictions with a diagnosis of pneumonia were under supervision. HIV infection was verified at 117 (70%) – I group. 109 (65%) patients has viral hepatitis (B, C, B+C) and 78 (47%) - tuberculosis (TB).Results: HCV viremia was strongly related to HIV infection (OR, 6.43; 95% CI, 2.21-17.51), but negatively correlated to HBsAg seropositivity (OR, 0.161; 95% CI, 0.082-0.317). 52 patients died. On stepwise logistic regression analysis, T CD4+ cell counts < or = 100/mm3 (p =.03), neutropenia (p =.02), PO2 arterial level < or = 70 mm Hg (p =.02), and Karnofsky score < or = 50 (p =.03) were independent indicators of mortality. When assessing the severity of pneumonia according to CURB-65, patients of group I were more often diagnosed with III or more points (61.5%), and group II - with II points (68.0%; x2=5.20, p=0.044). The average score on the SOFA scale was 6.2±1.8. 62 (53%) patients in group I had more than 25 points on the APACHE II scale. Severe sepsis was more often diagnosed in group I (51; x2=5.10, p=0.046), sepsis - in group II (14; x2=3.19, p=0.129), septic shock developed in 11 patients of group I and 4 patients of group II.Conclusion: in HIV-infected IDUs, the clinical picture is characterized by a severe course, an unfavorable prognosis with pronounced secondary manifestations of HIV and frequent complica-tions. With early diagnosis and adequate antimicrobial therapy in the absence of HIV, a favorable outcome of pneumonia can be expected.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2030.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -